Curevo’s lead asset, amezosvatein, is a Phase 3-ready shingles vaccine with potential to increase vaccination rates by delivering improved tolerability versus approved products Seattle, WA – May 26, 2026 – Curevo Vaccine (Curevo), a clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability, today announced entry into a definitive…Read More
“FLG Partners provided seasoned talent in Laureen DeBuono, as Interim CFO for over two years, to help scale Rodan+Field’s business, both operationally and strategically from $300M in net revenues in 2014 to $1.2B in 2016. What they delivered speaks for itself; a 5 year strategic plan including an annual operating plan, a new finance team, a renegotiated $200M line of credit and exit scenarios and strategies for the company. We would recommend FLG to any company looking for top-tier financial expertise and advice when scaling for explosive growth.”
